Results 271 to 280 of about 60,513 (321)

Gene Expression Analysis of Autophagy Markers in Primary and Secondary Myelofibrosis. [PDF]

J Clin Med
Medugorac M, Glick KM, Livun A, Lucijanic M, Galusic D, Kusec R.   +5 more
europepmc   +1 more source

Myelofibrosis: Treatment Options After Ruxolitinib Failure. [PDF]

Curr Oncol
Stuckey R, Segura Díaz A, Gómez-Casares MT.   +2 more
europepmc   +1 more source

Association of the composition of the bone marrow tumor microenvironment in BCR::ABL1-negative myeloproliferative neoplasms with IFN-γ signaling and driver mutations. [PDF]

Leukemia
Bauer M, Vaxevanis C, Jaekel N, Hackl H, Wilfer A, Zoellig C, Haemmerle M, Müller-Tidow C, Al-Ali HK, Seliger B, Wickenhauser C.   +10 more
europepmc   +1 more source

Indirect treatment comparison of momelotinib vs fedratinib safety in patients with myelofibrosis. [PDF]

Future Oncol
Masarova L, Verstovsek S, Palandri F, Mesa R, Harrison C, Sajeev G, Gorsh B, Simpson R, Cho S, Wang Z, Ellis C, Conlon S, Signorovitch J.   +12 more
europepmc   +1 more source

Ruxolitinib and Hepatitis-B Virus Reactivation: A Clinical Concern Requiring Prophylactic Management. [PDF]

Pak J Med Sci
Park JE, Yang J, Han S.
europepmc   +1 more source

Treatment patterns and healthcare resource utilization in ruxolitinib-treated patients with myelofibrosis with and without anemia: a real-world analysis. [PDF]

Ann Hematol
Liu T, Fillbrunn M, Zhang S, Chen J, Li W, Platt J, Niehoff N, Sajeev G, Signorovitch J.   +8 more
europepmc   +1 more source

Momelotinib Is Effective in Treatment for VEXAS Syndrome: Two Cases Within the AGMT Austrian Myeloid Registry. [PDF]

Eur J Haematol
Kiem D, Leisch M, Toth I, Mayer MC, Pleyer L, Greil R, Egle A, Melchardt T.   +7 more
europepmc   +1 more source

Durable response to venetoclax, azacytidine, and ruxolitinib in chronic-phase myelofibrosis resistant to ruxolitinib: a case report and literature review. [PDF]

Front Oncol
Liu X, Zhang X, Shi H.
europepmc   +1 more source